Publication: New insights into the performance of multigene panel testing: two novel nonsense variants in BRIP1 and TP53 in a young woman with breast cancer
Authors
Castillo-Guardiola, Verónica ; Marín-Vera, Miguel ; Sánchez-Bermúdez, Ana Isabel ; Alonso-Romero, José Luis ; Noguera Velasco, José Antonio ; Ruiz Espejo, Francisco ; Sarabia Meseguer, María Desamparados
item.page.secondaryauthor
item.page.director
Publisher
Elsevier
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1016/j.cancergen.2018.06.002
item.page.type
info:eu-repo/semantics/article
Description
© 2018 Elsevier Inc. All rights reserved. This document is the Published version of a Published Work that appeared in final form in Cancer Genetics. To access the final edited and published work see https://doi.org/10.1016/j.cancergen.2018.06.002
Abstract
Li-Fraumeni syndrome is an autosomal-dominant disorder caused by germline mutations in the tumour suppressor gene TP53. Here we report the case of a family whose index case was a woman diagnosed with bilateral breast cancer at the age of 18 and who had a non-informative result after BRCA1 and BRCA2 testing. After extending the study through multigene panel testing, two clinically relevant variants in the TP53 and BRIP1 genes, respectively, were found. Afterwards, the patient developed a glioblastoma. Both tumours were consistent with Li-Fraumeni syndrome. Thanks to the possibility of studying different genes related with hereditary breast and ovarian cancer, it was possible to find out the gene variant that caused the early onset cancers in the patient. Furthermore, genetic counselling was provided to the index case and her family.
publication.page.subject
Citation
Cancer Genetics 228–229 (2018) 1–4
item.page.embargo
Collections
Ir a Estadísticas
Sin licencia Creative Commons.